CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: Blood and skin comparisons by flow cytometry

Journal of Autoimmunity

Volumn 14, Issue 1, 2000, Pages 63-78

  Ferenczi, K ^a   Burack, L ^a   Pope, M ^a   Krueger, J G ^a   Austin, L M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Chronic activation; Flow cytometry; Psoriasis; T lymphocytes

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CD69 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL SUSPENSION; CLINICAL ARTICLE; CONTROLLED STUDY; DERMIS; EPIDERMIS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0033953110     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1999.0343     Document Type: Article

References (86)

1. Weinshenker B.G., Bass B.H., Ebers G.C., Rice G.P.A. Remission of psoriatic lesions with muromonab-CD3 (Orthoclone OKT3) treatment. J. Am. Acad. Dermatol. 20:1989;1132-1133.
2. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1995;442-447.
3. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S., Menter A., Lowe N.J., Krueger G., Brown M.J., Weiner R.S., Birkhofer M.J., Warner G.L., Berry K.K., Linsley P.S., Krueger J.G., Ochs H.D., Kelley S.L., Kang S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103:1999;1243-1252.
4. Vallat V.P., Gilleaudeau P., Battat L., Wolfe J., Heftler N., Gottlieb S.L., Hodak E., Gottlieb A.B., Krueger J.G. PUVA bath therapy with 8-methoxypsoralen. G. Weinstein, A.B. Gottlieb. Therapy of Moderate-to-Severe psoriasis. 1993;39-55 National Psoriasis Foundation, Portland.
5. Coven T.R., Murphy F.P., Gilleaudeau P., Cardinale I., Krueger J.G. Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris. Evidence that epidermal immunocytes are direct therapeutic targets. Arch. Dermatol. 134:1998;1263-1268.
6. Coven T.R., Burack L.H., Gilleaudeau P., Keogh M., Ozawa M., Krueger J.G. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch. Dermatol. 133:1997;1514-1522.
7. Ozawa M., Ferenczi K., Kikuchi T., Cardinale I., Austin L.M., Coven T.R., Burack L.H., Krueger J.G. 312-nanometer Ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J. Exp. Med. 189:1999;711-718.
8. Ellis C.N., Gorsulowsky D.C., Hamilton T.A., Billings J.K., Brown M.D., Headington J.T., Cooper K.D., Baadsgaard O., Duell E.A., Annesley T.M., Turcotte J.G., Voorhees J.J. Cyclosporine improves psoriasis in a double-blind study. J. Amer. Med. Assoc. 256:1986;3110-3116.
9. Baker B.S., Griffiths C.E.M., Lambert S., Powles A.V., Leonard J.N., Valdimarsson H., Fry L. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Brit. J. Dermatol. 116:1987;503-510.
10. Abu-Elmagd K., Van Thiel D., Jegasothy B.V., Ackerman C.D., Todo S., Fung J.J., Thomson A.W., Starzl T.E. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant. Proc. 23:1991;3322-3324.
11. Thomson A.W., Nalesnik M., Abu-Elmagd K., Starzl T.E. Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. Transplant. Proc. 23:1991;3330-3331.
12. Nikolaidis N.L., Abu-Elmagd K., Thomson A.W., Rilo H.R., Irish W.D., Van Thiel D.H., Fung J.J., Starzl T.E. Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. Transplant. Proc. 23:1991;3325-3327.
13. Gupta A.K., Baadsgaard O., Ellis C.N., Voorhees J.J., Cooper K.D. Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A. Arch. Dermatol. Res. 281:1989;219-226.
14. Hatakeyama M., Tsudo M., Minamoto S., Kono T., Doi T., Miyata T., Miyasaka M., Taniguchi T. Interleukin-2 receptor beta chain gene: generation of the three receptor forms by cloned human alpha and beta chain cDNAs. Science. 244:1989;551-556.
15. Hatakeyama M., Mori H., Doi T., Taniguchi T. A restricted cytoplasmic region of IL-2 receptor beta chain is essential for growth signal transduction but not for ligand binding and internalization. Cell. 59:1989;837-845.
16. Ralfkiaer E., Bosq J., Gatter K.C., Schwarting R., Gerdes J., Stein H., Mason D.Y. Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki- 1) in cutaneous lymphoid infiltrates. Arch. Dermatol. Res. 279:1987;285-292.
17. Romagnani S. Lymphokine production by human T cells in disease states. Ann. Rev. Immunol. 12:1994;227-257.
18. Del Prete G., De Carli M., Almerigogna F., Daniel C.K., D'Elios M.M., Zancuoghi G., Vinante F., Pizzolo G., Romagnani S. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J. 9:1995;81-86.
19. Leonard C., Tormey V., Burke C., Poulter L.W. Allergen-induced cytokine production in atopic disease and its relationship to disease severity. Amer. J. Resp. Cell & Mol. Biol. 17:1997;368-375.
20. Manetti R., Annunziato F., Biagliotti R., Giudizi M.G., Piccinni M.-P., Giannarini L., Sampognaro S., Parronchi P., Vinante F., Pizzolo G., Maggi E., Romagnani S. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection. J. Exp. Med. 180:1994;2407-2411.
21. Arnaout M.A. Leukocyte adhesion molecules deficiency: its structural basis, pathophysiology and implications for modulating the inflammatory response. Immunol. Rev. 114:1990;145-180.
22. Springer T.A. Adhesions receptors of the immune system. Nature. 346:1990;425-434.
23. Wright S.D., Jong M.T. Adhesion-promoting receptors on human macrophages recognize Escherichia coli by binding to lipopolysaccharide. J. Exp. Med. 164:1986;1876-1888.
24. Bullock W.E., Wright S.D. Role of the adherence-promoting receptors, CR3, LFA-1 and p150,95, in binding of Histoplasma capsulatum by human macrophages. J. Exp. Med. 165:1987;195-210.
25. Mosser D.M., Edelson P.J. The mouse macrophage receptor for C3bi (CR3) is a major mechanism in the phagocytosis of Leishmania promastigotes. J. Immunol. 135:1985;2785-2789.
26. Russell D.G., Wright S.D. Complement receptor type 3 (CR3) binds to an Arg-Gly-Asp-containing region of the major surface glycoprotein, gp63, of Leishmania promastigotes. J. Exp. Med. 168:1988;279-292.
27. Bos J.D., Hulsebosch H.J., Krieg S.R., Bakker P.M., Cormane R.H. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch. Dermatol. Res. 275:1983;181-189.
28. Baker B.S., Swain A.F., Fry L., Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br. J. Dermatol. 110:1984;555-564.
29. Gottlieb A.B., Lifshitz B., Fu S.M., Staiano-Coico L., Wang C.Y., Carter D.M. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J. Exp. Med. 164:1986;1013-1028.
30. Jones J.L., Berth-Jones J., Fletcher A., Hutchinson P.E. Assessment of epidermal dendritic cell markers and T-lymphocytes in psoriasis. J. Path. 174:1994;77-82.
31. Griffiths C.E.M., Voorhees J.J., Nickoloff B.J. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. J. Amer. Acad. Dermatol. 20:1989;617-629.
32. de Boer O.J., van der Loos C.M., Hamerlinck F., Bos J.D., Das P.K. Reappraisal of in situ immunophenotypic analysis of psoriasis skin: interaction of activated HLA-DR+immunocompetent cells and endothelial cells is a major feature of psoriatic lesions. Arch. Dermatol. Res. 286:1994;87-96.
33. Austin L.M., Coven T.R., Bhardwaj N., Steinman R., Krueger J.G. Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17 (TIA-1)+CD8+CD3+CTLs as determined by phenotypic analysis. J. Cutan. Pathol. 25:1998;79-88.
34. Pope M., Betjes M.G.H., Hirmand H., Hoffman L., Steinman R.M. Both dendritic cells and memory T lymphocytes emigrate from organ cultures of human skin and form distinctive dendritic-T-cell conjugates. J. Invest. Dermatol. 104:1995;11-17.
35. Poggi A., Bottino C., Zocchi M.R., Pantaleo G., Ciccone E., Mingari C., Moretta L., Moretta A. CD3+WT31- peripheral T lymphocytes lack T44 (CD28), a surface molecule involved in activation of T cells bearing the alpha/beta heterodimer. Eur. J. Immunol. 17:1987;1065-1068.
36. Austin L.M., Maki Ozawa, Toyoko Kikuchi, Walters I.B., Krueger a.J.G. The majority of epidermal T cells in psoriasis vulgaris lesions can produce Type 1 cytokines IFN-γ, IL-2 and TNF-α, defining TC1 (CTL) and TH1 effector populations: a Type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. in press. 1999.
37. Testi R., Phillips J.H., Lanier L.L. T cell activation via Leu-23 (CD69). J. Immunol. 143:1989;1123-1128.
38. Testi R., Phillips J.H., Lanier L.L. Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase C. J. Immunol. 142:1989;1854-1860.
39. Caruso A., Licenziati S., Corulli M., Canaris A.D., De Francesco M.A., Fiorentini S., Peroni L., Fallacara F., Dima F., Balsari A., Turano A. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry. 27:1997;71-76.
40. Morhenn V.B., Abel E.A., Mahrle G. Expression of HLA-DR antigen in skin from patients with psoriasis. J. Invest. Dermatol. 78:1982;165-168.
41. Bos J.D., Hulsebosch H.J., Krieg S.R., Bakker P.M., Cormane R.H. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch. Dermatol. Res. 275:1983;181-189.
42. Fernandez-Gutierrez B., Hernandez-Garcia C., Banares A.A., Jover J.A. Characterization and regulation of CD69 expression on rheumatoid arthritis synovial fluid T cells. J. Rheumatol. 22:1995;413-420.
43. Hovdenes J., Gaudernack G., Kvien T.K., Egeland T. Expression of activation markers on CD4+ and CD8+ cells from synovial fluid, synovial tissue and peripheral blood of patients with inflammatory arthritides. Scand. J. Immunol. 29:1989;631-639.
44. Afeltra A., Galeazzi M., Sebastiani G.D., Ferri G.M., Caccavo D., Addessi M.A., Marcolongo R., Bonomo L. Coexpression of CD69 and HLADR activation markers on synovial fluid T lymphocytes of patients affected by rheumatoid arthritis: a three-colour cytometric analysis. Int. J. Exp. Pathol. 78:1997;331-336.
45. Sheu B.C., Lin R.H., Ho H.N., Huang S.C. Down-regulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma. Hum. Immunol. 56:1997;39-48.
46. Nickoloff B.J., Nestle F.O., Zheng X.-G., Turka L.A. T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: A ligand for CD28. Blood. 83:1994;2580-2586.
47. Nestle F.O., Turka L.A., Nickoloff B.J. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest. 94:1994;202-209.
48. Imagawa A., Hanafusa T., Itoh N., Miyagawa J., Nakajima H., Namba M., Kuwajima M., Tamura S., Kawata S., Matsuzawa Y., Harlan D.M. Islet-infiltrating T lymphocytes in insulin-dependent diabetic patients express CD80 (B7-1) and CD86 (B7-2). J. Autoimmun. 9:1996;391-396.
49. Uyemura K., Yamamura M., Fivenson D.F., Modlin R.L., Nickoloff B.J. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J. Invest. Dermatol. 101:1993;701-705.
50. Schlaak J.F., Buslau M., Jochum W., Hermann E., Girndt M., Gallati H., Meyer zum Bueschenfelde K.-H. T cells involved in psoriasis vulgaris belong to the Th 1 subset. J. Invest. Dermatol. 102:1994;145-149.
51. Asadullah K., Sterry W., Stephanek K., Jasulaitis D., Leupold M., Audring H., Volk H.-D., Docke W.-D. IL-10 is a key cytokine in psoriasis. J. Clin. Invest. 101:1998;783-794.
52. Gerli R., Muscat C., Bistoni O., Falini B., Tomassini C., Agea E., Tognellini R., Biagini P., Bertotto A. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin. Exp. Immunol. 102:1995;547-550.
53. Morita Y., Yamamura M., Kawashima M., Harada S., Tsuji K., Shibuya K., Maruyama K., Makino H. Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arth. Rheum. 41:1998;1669-1676.
54. Kasteler J.S., Petersen M.J., Vance J.E., Zone J.J. Circulating activated T lymphocytes in autoeczematization. Arch. Dermatol. 128:1992;795-798.
55. Jeffes E.W.B., III, Lee G.C., Said S., Sabahi M., McCullough J.L., Herrod R., Alzona C.P., Linden K.G., Soundararajan D., Edwards S., Weinstein G.D. Elevated numbers of proliferating mononuclear cells in the peripheral blood of psoriatic patients correlate with disease severity. J. Invest. Dermatol. 105:1995;733-738.
56. Baker B.S., Swain A.F., Valdimarsson H., Fry L. T-cell subpopulations in the blood and skin of patients with psoriasis. Br. J. Dermatol. 110:1984;37-44.
57. Kokelj F., Perticarari S., Presani G., Trevisan G. An analysis of T-lymphocyte subpopulations in psoriasis using monoclonal antibodies. Acta. Derm. Venereol. (Stockh). 63:1983;422-424.
58. Gessl A., Waldhausl W. Increased CD69 and human leukocyte antigen-DR expression on T lymphocytes in insulin-dependent diabetes mellitus of long standing. J. Clin. Endocrinol. Metab. 83:1998;2204-2209.
59. Gessl A., Waldhausl W. Elevated CD69 expression on naive peripheral blood T-cells in hyperthyroid Graves' disease and autoimmune thyroiditis: discordant effect of methimazole on HLA-DR and CD69. Clin. Immunol. Immunopathol. 87:1998;168-175.
60. Crispin J.C., Martinez A., de Pablo P., Velasquillo C., Alcocer-Varela J. Participation of the CD69 antigen in the T-cell activation process of patients with systemic lupus erythematosus. Scand. J. Immunol. 48:1998;196-200.
61. Hemar A., Subtil A., Lieb M., Morelon E., Hellio R., Dautry-Varsat A. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta and gamma chains. J. Cell. Biol. 129:1995;55-64.
62. Lee R.E., Gaspari A.A., Lotze M.T., Chang A.E., Rosenberg S.A. Interleukin 2 and psoriasis. Arch. Dermatol. 124:1988;1811-1815.
63. De Pita O., Ruffelli M., Cadoni S., Frezzolini A., Biava G.F., Simom R., Bottari V., De Sanctis G. Psoriasis: comparison of immunological markers in patients with acute and remission phase. J. Dermatol. Sci. 13:1996;118-124.
64. Chang J.C.C., Smith L.R., Froning K.J., Schwabe B.J., Laxer J.A., Caralli L.L., Kurland H.H., Karasek M.A., Wilkinson D.I., Carlo D.J., Brostoff S.W. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor Vβ3 and/or Vβ13.1 genes. PNAS J. 91:1994;9282-9286.
65. Gray E.D., Regelmann W.E., Abdin Z., el Kholy A., Zaher S., Kamel R., Mansour M., Miller L., Ferrieri P., Zabriskie J.B., Braun D. Compartmentalization of cells bearing 'rheumatic' cell surface antigens in peripheral blood and tonsils in rheumatic heart disease. J. Infect. Dis. 155:1987;247-252.
66. Hamann D., Baars P.A., Rep M.H.G., Hooibrink B., Kerkhof-Garde S.R., Klein M.R., van Lier R.A.W. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 186:1997;1407-1418.
67. Rutella S., Rumi C., Lucia M.B., Etuk B., Cauda R., Leone G. Flow cytometric detection of perforin in normal human lymphocyte subpopulations defined by expression of activation/differentiation antigens. Immunol. Lett. 60:1998;51-55.
68. Wallis W.J., Hickstein D.D., Schwartz B.R., June C.H., Ochs H.D., Beatty P.G., Klebanoff S.J., Harlan J.M. Monoclonal antibody-defined functional epitopes on the adhesion-promoting glycoprotein complex (CDw 18) of human neutrophils. Blood. 67:1986;1007-1013.
69. van de Kerkhof P.C., Lammers A.M. Intraepidermal accumulation of polymorphonuclear leukocytes in chronic stable plaque psoriasis. Dermatologica. 174:1987;224-227.
70. Altieri D.C., Bader R., Mannucci P.M., Edgington T.S. Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J. Cell. Biol. 107:1988;1893-1900.
71. Diamond M.S., Alon R., Parkos C.A., Quinn M.T., Springer T.A. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J. Cell. Biol. 130:1995;1473-1482.
72. Leonard W., Depper J, Crabtree G., Rudikoff S., Pumphrey J., Robb R., Kronke M., Svetlik P., Peffer N., Waldman T., Greene W. Molecular cloning and expression of cDNAs for the human interleukin 2 receptor. Nature. 311:1984;626.
73. Robb R.J., Greene W.C. Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen. J. Exp. Med. 158:1983;1332-1337.
74. Sharon, M. Klausner, R.D. Cullen, B.R. Chizzonite, R. Leonard, W.J. 1986, Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science, 234, 859, 863.
75. Moretta A., Panteleo G., Lopez-Botet M., Moretta L. Involvement of T44 molecules in an antigen-independent pathway of T cell activation. Analysis of the correlations to the T cell antigen-receptor complex. J. Exp. Med. 162:1985;823-838.
76. Hara T., Jung L.K.L., Bjorndahl J.M, Fu S.M. Human T cell activation III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked Early Activation (EA-1) by 12-o-tetrdeanoyl phorbol-13-acetate, mitogens, and antigens. J. Exp. Med. 164:1986;1988-2005.
77. Yokochi T., Holly R.D., Clark E.A. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J. Immunol. 128:1982;823-827.
78. Clark E.A, Ledbetter J.A. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci U S A. 83:1986;4494-4498.
79. Caux C., Vanbervliet B., Massacrier C., Azuma M., Okumura K, Lanier L.L., Banchereau J. B70/B7-2 is identical to CD86 and is the mamor funtional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. 180:1994;1841-1847.
80. Brunet J.F., Denizot F., Luciani M.F., Roux-Dosseto M., Suzan M., Mattei M.G., Goldstein P. A new member of the immunoglobulin superfamily - CTLA-4. Nature. 328:1987;267-270.
81. Dariavach P., Mattei M.G., Goldstein P., Lefranc M.P. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur. J. Immunol. 18:1988;1901-1905.
82. Stein H., Gerdes J., Schwab U., Lemke H., Diehl V., Mason D.Y., Bartels H, Ziegler A. Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells. Hematol. Oncol. 1:1983;21-29.
83. Springer T., Galfre G., Secher D.S., Milstein C. Mac-1: a macrophage differentiation antigen identified by monoclonal antibody. Eur. J. Immunol. 9:1979;301-306.
84. Trowbridge I.S., Omary M.B. Molecular complexity of leukocyte surface glycoproteins related to the macrophage differentiation antigen Mac-1. J. Exp. Med. 154:1981;1517-1524.
85. Coven T.R., Murphy F.P., Gilleadeau P., Hayes E., Krueger J.G. 6-thioguanine induces selective apoptosis in lymphocytes -remittive anti-psoriatic effects correlate with depletion of activated lymphocytes from lesional skin. J. Invest. Dermatol. 106:1996;948.
86. Gottlieb A.B., Krueger R., Bright R., Ling M., Lebwohl M., Kang S, Feldman S., Spellman M., Garovoy M. Phase 1 trial of psoriasis with an anti-CD11A (LFA-1) monoclonal antibody (MAB). J. Invest. Dermatol. 110:1998;679.